Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabigatran pharmacokinetic and pharmacodynamic study in moderate renal impairment after elective knee or hip replacement
NL-OMON34322Phase 4Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dabigatran in venous thromboembolism (VTE), sponsored by Boehringer Ingelheim. Primary endpoints: Clotting time and calculated dabigatran plasma concentration, Activated partial thromboplastin time and 5 more. Started Jun 2010; status: active, not recruiting.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NL-OMON34322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34322.